Liu Qi, Shan Zezhi, Luo Dakui, Zhang Sheng, Li Qingguo, Li Xinxiang
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Front Oncol. 2021 Feb 24;11:574772. doi: 10.3389/fonc.2021.574772. eCollection 2021.
Based on a prognostic scoring system ( score) proposed by us recently, this retrospective large population-based and propensity score-matched (PSM) study focused on predicting the survival benefit of adjuvant CT in stage II disease.
Patients diagnosed with stage II colon cancer (N = 73397) were identified from the Surveillance, Epidemiology, and End Results database between January 1, 1988 and December 31, 2005 and divided into the CT and non-CT groups. PSM balanced the patient characteristics between the CT and non-CT groups.
The magnitude of CSS improvement among patients treated with adjuvant CT was significantly associated with the P score, score 8 [hazard ratio (HR) = 0.580, 95% confidence interval (CI) = 0.323-1.040, P = 0.067] was associated with a much higher increased CSS benefit among patients treated with adjuvant CT as compared to score 2* (*, including scores 0, 1, and 2; HR = 1.338, 95% CI = 1.089-1.644, P = 0.006).
High scores were demonstrated to be associated with superior survival benefit of adjuvant CT. Therapy decisions of adjuvant CT in stage II colon cancer could be tailored on the basis of tumor biology, patient characteristics and the score.
基于我们最近提出的一种预后评分系统（评分），这项回顾性大样本人群及倾向评分匹配（PSM）研究聚焦于预测Ⅱ期疾病辅助化疗（CT）的生存获益。
从监测、流行病学和最终结果数据库中识别出1988年1月1日至2005年12月31日期间诊断为Ⅱ期结肠癌的患者（N = 73397），并将其分为CT组和非CT组。PSM平衡了CT组和非CT组之间的患者特征。
接受辅助CT治疗的患者中，癌症特异性生存（CSS）改善程度与P评分显著相关，评分8[风险比（HR）= 0.580，95%置信区间（CI）= 0.323 - 1.040，P = 0.067]与接受辅助CT治疗的患者相比，其CSS获益增加幅度远高于评分2*（*，包括评分0、1和2；HR = 1.338，95% CI = 1.089 - 1.644，P = 0.006）。
高评分被证明与辅助CT的优越生存获益相关。Ⅱ期结肠癌辅助CT的治疗决策可根据肿瘤生物学、患者特征和评分来制定。
